Promising drug targets childhood eye muscle disease
NCT ID NCT07298928
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called Telitacicept in 30 children with ocular myasthenia gravis, a condition that causes droopy eyelids and double vision. The drug aims to reduce relapses and the need for steroids. It is given as a weekly shot alongside standard care. The trial is open-label and early-stage, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telitacicept (a targeted B-cell biologic drug given as a shot)
What this could lead to
If it works, this could offer a new treatment option for children with ocular myasthenia gravis, reducing relapses and the need for steroids.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be conclusive. The drug also carries risks like infection and is not yet approved for children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EFFECTIVENESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Affiliated to Shandong University
Jinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shenzhen children's Hospital of China Medical University
Shenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••